Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia

BackgroundHypoxia is a hallmark of solid tumors and is associated with metastases, therapeutic resistance and poor patient survival.ResultsIn this study, we showed that hypoxia protected MDA-MB-231 breast cancer cells against paclitaxel- but not epirubicin-induced apoptosis. The possible implication of HIF-1 and AP-1 in the hypoxia-induced anti-apoptotic pathway was investigated by the use of specific siRNA. Specific inhibition of the expression of these two transcription factors was shown to increase apoptosis induced by chemotherapeutic agents under hypoxia indicating an involvement of HIF-1 and AP-1 in the anti-apoptotic effect of hypoxia. After HIF-1 specific inhibition and using TaqMan Human Apoptosis Array, 8 potential HIF-1 target genes were identified which could take part in this protection. Furthermore, Mcl-1 was shown to be a potential AP-1 target gene which could also participate to the hypoxia-induced chemoresistance.ConclusionsAltogether, these data highlight two mechanisms by which hypoxia could mediate its protective role via the activation of two transcription factors and, consecutively, changes in gene expression encoding different anti- and pro-apoptotic proteins.

[1]  E. Cummins,et al.  Hypoxia-responsive transcription factors , 2005, Pflügers Archiv.

[2]  Jun O. Liu,et al.  Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells , 2009, Proceedings of the National Academy of Sciences.

[3]  Qiaojun He,et al.  Hypoxia-mediated fenretinide (4-HPR) resistance in childhood acute lymphoblastic leukemia cells , 2006, Cancer Chemotherapy and Pharmacology.

[4]  J M Brown,et al.  Tumor hypoxia, drug resistance, and metastases. , 1990, Journal of the National Cancer Institute.

[5]  D. Mottet,et al.  Is HIF-1α a pro- or an anti-apoptotic protein? ☆ , 2002 .

[6]  I. Tannock,et al.  Drug resistance and the solid tumor microenvironment. , 2007, Journal of the National Cancer Institute.

[7]  A. Ashkenazi,et al.  Apo2L/TRAIL and its death and decoy receptors , 2003, Cell Death and Differentiation.

[8]  N. Kröger,et al.  Current options in treatment of anthracycline-resistant breast cancer. , 1999, Cancer treatment reviews.

[9]  E. Minet,et al.  Hypoxia-inducible Factor-1-dependent Overexpression of Myeloid Cell Factor-1 Protects Hypoxic Cells against tert-Butyl Hydroperoxide-induced Apoptosis* , 2005, Journal of Biological Chemistry.

[10]  P. Ratcliffe,et al.  Oxygen-regulated and Transactivating Domains in Endothelial PAS Protein 1: Comparison with Hypoxia-inducible Factor-1α* , 1999, The Journal of Biological Chemistry.

[11]  G. Song,et al.  Role of hypoxia in the hallmarks of human cancer , 2009, Journal of cellular biochemistry.

[12]  P. O'dwyer,et al.  Role of Jun and Jun kinase in resistance of cancer cells to therapy. , 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[13]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[14]  E. Stanbridge,et al.  Regulation of gene expression by hypoxia: integration of the HIF-transduced hypoxic signal at the hypoxia-responsive element. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[15]  R. Zhao,et al.  Knockdown of hypoxia-inducible factor-1alpha in breast carcinoma MCF-7 cells results in reduced tumor growth and increased sensitivity to methotrexate. , 2006, Biochemical and biophysical research communications.

[16]  F. de Longueville,et al.  Hypoxia induces protection against etoposide-induced apoptosis: molecular profiling of changes in gene expression and transcription factor activity , 2008, Molecular Cancer.

[17]  M. Simon,et al.  Hypoxia-inducible factors: central regulators of the tumor phenotype. , 2007, Current opinion in genetics & development.

[18]  C. Dang,et al.  Effects of hypoxia on tumor metabolism , 2007, Cancer and Metastasis Reviews.

[19]  L. Huang,et al.  Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway , 1998 .

[20]  R. McCarron,et al.  Antiapoptotic action of hypoxia-inducible factor-1 alpha in human endothelial cells. , 2004, Laboratory investigation; a journal of technical methods and pathology.

[21]  C. Akgul Mcl-1 is a potential therapeutic target in multiple types of cancer , 2009, Cellular and Molecular Life Sciences.

[22]  D. Hussein,et al.  Chronic hypoxia promotes hypoxia-inducible factor-1α–dependent resistance to etoposide and vincristine in neuroblastoma cells , 2006, Molecular Cancer Therapeutics.

[23]  L. del Peso,et al.  Hypoxia Induces the Activation of the Phosphatidylinositol 3-Kinase/Akt Cell Survival Pathway in PC12 Cells , 2001, The Journal of Biological Chemistry.

[24]  G. Bertelli,et al.  Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E. Z. Yu,et al.  HIF-1alpha has an anti-apoptotic effect in human airway epithelium that is mediated via Mcl-1 gene expression. , 2006, Journal of cellular biochemistry.

[26]  Shuang-yin Han,et al.  Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. , 2008, Cancer science.

[27]  Aoife M Shannon,et al.  Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. , 2003, Cancer treatment reviews.

[28]  A. Patterson,et al.  Can gene therapy overcome the problem of hypoxia in radiotherapy? , 2000, Journal of radiation research.

[29]  P. Brown,et al.  Inducible overexpression of c-Jun in MCF7 cells causes resistance to vinblastine via inhibition of drug-induced apoptosis and senescence at a step subsequent to mitotic arrest. , 2007, Biochemical pharmacology.

[30]  A. Giaccia,et al.  The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. , 1998, Cancer research.

[31]  Xianrang Song,et al.  Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1α gene , 2006, Cancer Chemotherapy and Pharmacology.

[32]  S. Menéndez,et al.  Cell Autonomous Apoptosis Defects in Acid Sphingomyelinase Knockout Fibroblasts* , 2001, The Journal of Biological Chemistry.

[33]  Janice M. Y. Brown,et al.  The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. , 1999, Cancer research.

[34]  J. Eberle,et al.  Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). , 2005, The Journal of investigative dermatology.

[35]  M. Ivan,et al.  HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.

[36]  P. Malmström,et al.  TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer , 2006, Acta oncologica.

[37]  C. Michiels,et al.  Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. , 2008, Anti-cancer agents in medicinal chemistry.

[38]  M. Raes,et al.  Differential effects of hypoxia on etoposide-induced apoptosis according to the cancer cell lines , 2007, Molecular Cancer.

[39]  K. Fışkın,et al.  Epirubicin HCl toxicity in human-liver derived hepatoma G2 cells. , 2004, Polish journal of pharmacology.

[40]  Shi-Yong Sun,et al.  Modulation of death receptors by cancer therapeutic agents , 2008, Cancer biology & therapy.

[41]  R. Bruick Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[42]  G. Fountzilas,et al.  Paclitaxel: epirubicin in metastatic breast cancer--a review. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  S. Kitano,et al.  Transcriptional Regulation by Transforming Growth Factor β of the Expression of Retinoic Acid and Retinoid X Receptor Genes in Osteoblastic Cells Is Mediated through AP-1* , 1996, The Journal of Biological Chemistry.

[44]  G. Semenza Mitochondrial autophagy: Life and breath of the cell , 2008, Autophagy.

[45]  C. Bokemeyer,et al.  Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro , 2003, British Journal of Cancer.

[46]  Dale E. Bredesen,et al.  Caspase Cleavage of Gene Products Associated with Triplet Expansion Disorders Generates Truncated Fragments Containing the Polyglutamine Tract* , 1998, The Journal of Biological Chemistry.

[47]  M. Raes,et al.  Hypoxia protects HepG2 cells against etoposide-induced apoptosis via a HIF-1-independent pathway. , 2006, Experimental cell research.

[48]  Michael C. Montalto,et al.  Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. , 2002, Cancer research.

[49]  A. Harris,et al.  HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. , 2001, Cancer research.

[50]  Shuang-yin Han,et al.  Hypoxia‐inducible factor‐1α contributes to hypoxia‐induced chemoresistance in gastric cancer , 2007 .

[51]  D. Long,et al.  Effect of Hypoxia-inducible Factor-1α Silencing on the Sensitivity of Human Brain Glioma Cells to Doxorubicin and Etoposide , 2009, Neurochemical Research.

[52]  R. Marciniak,et al.  Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) , 2004, Cancer Gene Therapy.

[53]  D. Peet,et al.  FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. , 2002, Genes & development.

[54]  G. Semenza,et al.  Mitochondrial Autophagy Is an HIF-1-dependent Adaptive Metabolic Response to Hypoxia* , 2008, Journal of Biological Chemistry.

[55]  Y. Fong,et al.  Employing Tumor Hypoxia for Oncolytic Therapy in Breast Cancer , 2005, Journal of Mammary Gland Biology and Neoplasia.

[56]  B. Teicher Hypoxia and drug resistance , 1994, Cancer and Metastasis Reviews.

[57]  P. Vaupel,et al.  Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.

[58]  Crispin J. Miller,et al.  Hypoxia-Mediated Down-Regulation of Bid and Bax in Tumors Occurs via Hypoxia-Inducible Factor 1-Dependent and -Independent Mechanisms and Contributes to Drug Resistance , 2004, Molecular and Cellular Biology.

[59]  J. Pouysségur,et al.  Hypoxia and cancer , 2007, Journal of Molecular Medicine.

[60]  E. Z. Yu,et al.  HIF‐1α has an anti‐apoptotic effect in human airway epithelium that is mediated via Mcl‐1 gene expression , 2006 .

[61]  Mark W. Dewhirst,et al.  Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment , 2007, Cancer and Metastasis Reviews.

[62]  T. H. Wang,et al.  Paclitaxel‐induced cell death , 2000, Cancer.

[63]  R. McCarron,et al.  Antiapoptotic action of hypoxia-inducible factor-1α in human endothelial cells , 2004, Laboratory Investigation.

[64]  I. Fidler,et al.  Hypoxia Increases Resistance of Human Pancreatic Cancer Cells to Apoptosis Induced by Gemcitabine , 2004, Clinical Cancer Research.

[65]  P Vaupel,et al.  Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. , 1991, Cancer research.

[66]  D. Mottet,et al.  Is HIF-1alpha a pro- or an anti-apoptotic protein? , 2002, Biochemical pharmacology.

[67]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.